Tag: Ruth Gimeno
Lilly expands portfolio with $1.9bn acquisition of Versanis Bio
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a ... Read More
Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic ... Read More
Lilly to acquire clinical-stage biopharma company Versanis Bio
American pharma giant Eli Lilly and Company (Lilly) and Versanis Bio have announced a definitive agreement in which the former will acquire the privately-held clinical-stage ... Read More
Lilly to transform chronic disease management with Sigilon Therapeutics acquisition
Pharmaceutical giant Eli Lilly and Company (Lilly) has announced its definitive agreement to acquire Nasdaq-listed biopharma innovator Sigilon Therapeutics, in a move set to significantly ... Read More
Lilly takes full ownership of biotech company Protomer Technologies
Eli Lilly and Company (Lilly) has taken full ownership of California-based biotech company Protomer Technologies in a deal that is potentially worth more than $1 ... Read More